Coinfecção por vírus da imunodeficiência humana e coronavírus: perfil clínico-imunológico e alta hospitalar
| dc.contributor.advisor | Carvalho, Érica da Silva | |
| dc.contributor.advisor-lattes | http://lattes.cnpq.br/3325190814999717 | |
| dc.contributor.author | Ferreira, Millena Gomes | |
| dc.contributor.referee1 | Carvalho, Érica da Silva | |
| dc.contributor.referee1Lattes | http://lattes.cnpq.br/3325190814999717 | |
| dc.contributor.referee2 | Martins, Alex | |
| dc.contributor.referee2Lattes | http://lattes.cnpq.br/3661607448132704 | |
| dc.contributor.referee3 | Araújo, Felipe Queiroz | |
| dc.date.accessioned | 2026-09-15T17:39:38Z | |
| dc.date.issued | 2026-06-17 | |
| dc.description.abstract | To characterize the sociodemographic, clinical-immunological profile and discharge status of people living with HIV and COVID-19 co-infection admitted to a reference hospital in tropical medicine. Método: Retrospective cross-sectional study based on secondary data from medical records during the pandemic period, using descriptive analysis and guided by the STROBE guidelines. Resultados: In the 135 medical records analyzed, men predominated (71.1%) and the age range was 25 to 49 years (63.0%). Advanced immunosuppression was significant, with 46.7% of patients presenting CD4 counts below 200 cells/mm3 and 45.2% with irregular use of antiretroviral therapy (ART). Tuberculosis (26.7%) and neurotoxoplasmosis (26.7%) were the most frequent opportunistic diseases. Regarding the clinical evolution of the patients, 8.1% required ICU admission and discharge due to improvement was 88.9%. Conclusão: The described population is heterogeneous, evidencing the coexistence of a virologically controlled subgroup with another in an advanced stage of immunosuppression and failure in the continuum of care, inserted in a scenario of high hospital mortality due to coinfection. | |
| dc.description.resumo | Caracterizar o perfil sociodemográfico, clínico-imunológico e a condição de alta de pessoas vivendo com HIV e coinfecção por COVID-19 internadas em um hospital de referência em medicina tropical. Método: Estudo transversal retrospectivo baseado em dados secundários de prontuários do período pandêmico, utilizando análise descritiva e orientado pelo guia STROBE. Resultados: Nos 135 prontuários analisados, predominaram homens (71,1%) e a faixa etária de 25 a 49 anos (63,0%). A imunossupressão avançada foi marcante, com 46,7% dos pacientes apresentando CD4 inferior a 200 células/mm3 e 45,2% com uso irregular da terapia antirretroviral (TARV). Tuberculose (26,7%) e neurotoxoplasmose (26,7%) foram as doenças oportunistas mais frequentes. Quanto a evolução clínica dos pacientes, 8,1% necessitaram de UTI e a alta por melhora foi de 88,9%.Conclusão: A população descrita é heterogênea, evidenciando a coexistência de um subgrupo virologicamente controlado com outro em estágio avançado de imunossupressão e falha no continuum de cuidado, inseridos em um cenário de elevada letalidade hospitalar pela coinfecção. | |
| dc.identifier.citation | FERREIRA, Millena Gomes. Coinfecção por vírus da imunodeficiência humana e coronavírus: perfil clínico-imunológico e alta hospitalar . TCC (Bacharelado em Enfermagem). Manaus, UEA, 2026 | |
| dc.identifier.uri | https://ri.uea.edu.br/handle/riuea/8643 | |
| dc.publisher | Universidade do Estado do Amazonas | |
| dc.publisher.initials | UEA | |
| dc.relation.references | 1. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Boletim Epidemiológico HIV/Aids 2022. Brasília: Ministério da Saúde; 2022. 2. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol. 2010;10(1):11-23. doi:10.1038/nri2674 27 3. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020 [Internet]. Geneva: WHO; 2020 [citado 2026 mai 25]. Disponível em: https://www.who.int/director-general/speeches/detail/who-director- general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi:10.1016/S0140-6736(20)30566-3 5. Cogo CS, Sousa PPS, Fontes JLF. Impacto na prevenção, diagnóstico e tratamento de HIV/AIDS durante a pandemia da COVID-19. Brazilian Journal of Development. 2022;8(12):79510-27. doi:10.34117/bjdv8n12-179 6. Shiau S, Krause KD, Valera P, Swaminathan S, Halkitis PN. The burden of COVID-19 in people living with HIV: a syndemic perspective. AIDS Behav. 2020;24(8):2244-9. doi:10.1007/s10461-020-02871-9 7. Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E, et al. Outcomes among HIV-positive patients hospitalized with COVID-19. J Acquir Immune Defic Syndr. 2020;85(1):6-10. doi:10.1097/QAI.0000000000002423 8. Cooper TJ, Woodward BL, Alom S, Harky A. Coronavirus disease 2019 (COVID-19) outcomes in HIV/AIDS patients: a systematic review. HIV Med. 2020;21(9):567-77. doi:10.1111/hiv.12911 9. Mayer Alves M, Ribeiro Kormann J, Recarcati K, Texeira L, Texeira AC, Rozin L. Clinical consequences of COVID-19 on people with HIV/AIDS: an integrative literature review. Rev. Saúde Pública Paraná. 2021;4(1):108-118. 10. Wit FWNM, Reiss P, Rijnders B, Rokx C, Roukens A, Brinkman K, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in people with HIV in the 28 Netherlands: the ATHENA cohort study. AIDS. 2023;37(11):1671-81. doi:10.1097/QAD.0000000000003597 11. Heidary M, Asadi A, Noorbakhsh N, Dashtbin S, Asadollahi P, Dranbandi A, et al. COVID- 19 in HIV-positive patients: a systematic review of case reports and case series. J Clin Lab Anal. 2022;36(4):e24308. doi:10.1002/jcla.24308 12. Oliveira TNC, Queiroz MJ, Santos ALS, Carmo CN, Cunha GM, Leite IC, et al. COVID- 19 mortality among people living with HIV/AIDS in Brazil: a multilevel analysis. AIDS Res Ther. 2025;22:110. doi:10.1186/s12981-025-00759-z 13. Silva DG, Lima RCC, Oliveira FG, Otero SG, Natário RM, Pereira LTT, et al. Perfil epidemiológico de pacientes internados por HIV/AIDS no Brasil: revisão integrativa da literatura. Research, Society and Development. 2021;10(9):e19410917976. doi:10.33448/rsd-v10i9.17976 14. Manaus. Secretaria Municipal de Saúde. Boletim epidemiológico: doenças e agravos de notificação compulsória de maior incidência no município de Manaus, 2020-2024. Manaus: SEMSA; 2025. 15. Garcia PJ, Cabrera DM, Cárcamo PM, Diaz MM. HIV and COVID-19 in Latin America and the Caribbean. Curr HIV/AIDS Rep. 2022;19(1):37-45. doi:10.1007/s11904-021- 00589-4 16. Lembas A, Załęski A, Mikuła T, Dyda T, Stańczak W, Wiercińska-Drapało A. Evaluation of clinical biomarkers related to CD4 recovery in HIV-infected patients: 5-year observation. Viruses. 2022;14(10):2287. doi:10.3390/v14102287 17. Blanco JL, Ambrosioni J, Garcia F, Martínez E, Soriano A, Mallolas J, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020;7(5):e314-e316. doi:10.1016/S2352-3018(20)30111-9 29 18. Hoffmann C, Casado JL, Härter G, Vizcarra P, Moreno A, Cattaneo D, et al. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2021;22(5):372-8. doi:10.1111/hiv.13037 19. Augello M, Bono V, Rovito R, Tincati C, Marchetti G. Immunologic interplay between HIV/AIDS and COVID-19: adding fuel to the flames? Curr HIV/AIDS Rep. 2023;20(2):51-75. doi:10.1007/s11904-023-00647-z 20. Ukaegbu E, Maulenkul T, Sarria-Santamera A. Impact of COVID-19 on utilization of healthcare services among people living with HIV (PLHIV): a systematic review. Medicina (Kaunas). 2025;61(1):111. doi:10.3390/medicina61010111 21. Kanazawa A, Yan Y, Yuda M, Fukui N, Saita M, Mori H, et al. Risk factors for progressing to severe COVID-19 among people living with HIV in Japan: a hospital claims database study. J Infect Chemother. 2024;30(1):40-7. doi:10.1016/j.jiac.2023.09.009 22. González-Domenech CM, Pérez-Hernández I, Gómez-Ayerbe C, Viciana Ramos I, Palacios-Muñoz R, Santos J. A pandemic within other pandemics. When a multiple infection of a host occurs: SARS-CoV-2, HIV and Mycobacterium tuberculosis. Viruses. 2021;13(5):931. doi:10.3390/v13050931 23. Battistini Garcia SA, Zubair M, Guzman N. Contagem de células CD4 e HIV. [Atualizado em 2025 jan 19]. Em: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK513289 | |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | en |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
| dc.subject | Infecção por HIV | |
| dc.subject | COVID-19 | |
| dc.subject | Coinfecção | |
| dc.subject | Infecções oportunistas | |
| dc.title | Coinfecção por vírus da imunodeficiência humana e coronavírus: perfil clínico-imunológico e alta hospitalar | |
| dc.title.alternative | Human immunodeficiency virus and coronavirus coinfection: clinical-immunological profile and hospital discharge | |
| dc.type | Trabalho de Conclusão de Curso |
Arquivos
Pacote original
1 - 1 de 1
Carregando...
- Nome:
- Coinfecção_por_vírus_da_imunodeficiência.pdf
- Tamanho:
- 1.04 MB
- Formato:
- Adobe Portable Document Format